【Abstract】One of the major complications of atrial fibrillation is thromboembolic disease, and there is a risk of stent thrombosis after coronary stenting. Therefore, patients with atrial fibrillation complicated with coronary artery disease require antiplatelet and anticoagulation dual antithrombotic treatment, but the risk of bleeding is high. How to balance the risk of thrombosis and bleeding, the selection of appropriate antithrombotic strategy is the current clinical problem and research hotspot. With the advancement of coronary interventional techniques, the number of patients with atrial fibrillation complicated with coronary stenting has gradually increased, and triple or dual antiplatelet and anticoagulant of dual antithrombotic therapy based on warfarin or new oral anticoagulant the application is more and more extensive, and the bleeding risk is gradually increased. Establishing an effective bleeding prediction model to screen highrisk populations of bleeding helps to make clinical decisionmaking avoidance risks. This article reviews the current advantages and limitations of drug selection, drug combination, domestic and international guidelines and expert consensus recommendations for atrial fibrillation combined with coronary stenting and various bleeding scoring systems.